Tariferid (Tablets) Instructions for Use
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
ATC Code
J01MA01 (Ofloxacin)
Active Substance
Ofloxacin (Rec.INN registered by WHO)
Dosage Form
| Tariferid | Film-coated tablets 200 mg: blisters of 10 pcs., bags of 1000 pcs. |
Dosage Form, Packaging, and Composition
| Film-coated tablets | 1 tab. |
| Ofloxacin | 200 mg |
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (150) – cardboard boxes.
10 pcs. – contour cell packs (300) – cardboard boxes.
10 pcs. – contour cell packs (1000) – cardboard boxes.
10 pcs. – contour cell packs (2000) – cardboard boxes.
10 pcs. – contour cell packs (500) – cardboard boxes.
10 pcs. – contour cell packs (700) – cardboard boxes.
10 pcs. – contour cell packs (900) – cardboard boxes.
1000 pcs. – polymer jars (6) – cardboard boxes.
1000 pcs. – polymer jars (10) – cardboard boxes.
1000 pcs. – bags made of combined heat-sealable material (2) – cardboard boxes.
1000 pcs. – bags made of combined heat-sealable material (4) – cardboard boxes.
1000 pcs. – bags made of combined heat-sealable material (6) – cardboard boxes.
1000 pcs. – bags made of combined heat-sealable material (8) – cardboard boxes.
1000 pcs. – bags made of combined heat-sealable material (10) – cardboard boxes.
1000 pcs. – bags made of combined heat-sealable material (12) – cardboard boxes.
1000 pcs. – bags made of combined heat-sealable material (1) – cardboard boxes.
Clinical-Pharmacological Group
Antibacterial drug of the fluoroquinolone group
Pharmacotherapeutic Group
Antimicrobial agent – fluoroquinolone
Pharmacological Action
Antimicrobial agent of the fluoroquinolone group with a broad spectrum of action. The bactericidal action of ofloxacin is associated with the blockade of the DNA gyrase enzyme in bacterial cells.
It is highly active against most gram-negative bacteria: Escherichia coli, Salmonella spp., Shigella spp., Proteus spp., Morganella morganii, Klebsiella spp. (including Klebsiella pneumoniae), Enterobacter spp., Serratia spp., Citrobacter spp., Yersinia spp., Providencia spp., Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitidis, Mycoplasma spp., Legionella pneumophila, Acinetobacter spp., and also Chlamydia spp.
It is active against some gram-positive microorganisms (including Staphylococcus spp., Streptococcus spp., especially beta-hemolytic streptococci).
Enterococcus faecalis, Streptococcus pneumoniae, Pseudomonas spp. are moderately sensitive to ofloxacin.
Anaerobic bacteria (except Bacteroides urealyticus) are not sensitive to ofloxacin.
It is resistant to the action of beta-lactamases.
Pharmacokinetics
After oral administration, it is rapidly and completely absorbed from the gastrointestinal tract. Food intake slightly affects the extent of absorption but may slow its rate. Cmax in blood plasma is reached within 2 hours.
Protein binding is 25%. Ofloxacin is widely distributed in body tissues and fluids (organs of the urinary system, genital organs, prostate gland, lungs, ENT organs, gallbladder, bones, skin).
It is excreted in the urine unchanged (about 80% within 24 hours). Ofloxacin concentrations in the urine significantly exceeded the MIC90 for most microorganisms after the last dose (300 mg twice daily for 14 days). A small part of the active substance (about 4%) is excreted in the feces. T1/2 is 6 hours.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to ofloxacin, including: diseases of the lower respiratory tract, ear, throat, nose, skin, soft tissues, bones, joints, infectious and inflammatory diseases of the abdominal organs (except for bacterial enteritis) and pelvis, kidney and urinary tract infections, prostatitis, gonorrhea.
ICD codes
| ICD-10 code | Indication |
| A54 | Gonococcal infection |
| H66 | Suppurative and unspecified otitis media |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J31.2 | Chronic pharyngitis |
| J32 | Chronic sinusitis |
| J35.0 | Chronic tonsillitis |
| J37.1 | Chronic laryngotracheitis |
| K65.0 | Acute peritonitis (including abscess) |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K83.0 | Cholangitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| M00 | Pyogenic arthritis |
| M86 | Osteomyelitis |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N37.0 | Urethritis in diseases classified elsewhere |
| N41 | Inflammatory diseases of prostate |
| N70 | Salpingitis and oophoritis |
| N72 | Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis) |
| N74.3 | Gonococcal inflammatory diseases of female pelvic organs |
| N76 | Other inflammatory diseases of vagina and vulva |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1A7Z | Gonococcal infection, unspecified |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| AA9Z | Unspecified suppurative otitis media |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA09.2 | Chronic pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| DC50.0 | Primary peritonitis |
| DC50.2 | Peritoneal abscess |
| DC50.Z | Peritonitis, unspecified |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| FA1Z | Infectious arthropathies, unspecified |
| FB84.Z | Osteomyelitis or osteitis, unspecified |
| GA00 | Vulvitis |
| GA02.Z | Unspecified vaginitis |
| GA07.Z | Salpingitis and oophoritis, unspecified |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.1 | Nonspecific urethritis |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| 1A71 | Gonococcal pelviperitonitis |
| GA05.Z | Inflammatory diseases of female pelvic organs, unspecified |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| XA5WW1 | Cervix uteri |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
It is set individually, taking into account the severity and localization of the infection, and the sensitivity of the pathogen.
Orally, it is prescribed in a daily dose of 200-800 mg, with a frequency of administration of 2 times/day. For patients with impaired renal function (CrCl 20-50 ml/min), the first dose is 200 mg, then 100 mg every 24 hours. With CrCl less than 20 ml/min, the first dose is 200 mg, then 100 mg every 48 hours.
Adverse Reactions
From the digestive system nausea, vomiting, diarrhea, abdominal pain and cramps, loss of appetite, dry mouth, flatulence, gastrointestinal dysfunction, constipation; rarely – liver dysfunction, liver necrosis, jaundice, hepatitis, intestinal perforation, pseudomembranous colitis, gastrointestinal bleeding, disorders of the oral mucosa, heartburn, increased activity of liver enzymes, including GGT and LDH, increased serum bilirubin level.
From the nervous system insomnia, dizziness, fatigue, drowsiness, nervousness; rarely – convulsions, anxiety, cognitive changes, depression, abnormal dreams, euphoria, hallucinations, paresthesia, syncope, tremor, confusion, nystagmus, suicidal thoughts or attempts, disorientation, psychotic reactions, paranoia, phobia, agitation, aggressiveness, emotional lability, peripheral neuropathy, ataxia, coordination disorders, exacerbation of extrapyramidal disorders, speech disorder.
Allergic reactions skin rash, itching; rarely – angioedema, urticaria, vasculitis, allergic pneumonitis, anaphylactic shock, erythema multiforme, Stevens-Johnson syndrome, erythema nodosum, exfoliative dermatitis, toxic epidermal necrolysis, conjunctivitis.
From the reproductive system itching in the external genital area in women, vaginitis, vaginal discharge; rarely – burning, irritation, pain and rash in the genital area in women, dysmenorrhea, menorrhagia, metrorrhagia, vaginal candidiasis.
From the cardiovascular system rarely – cardiac arrest, edema, arterial hypertension, arterial hypotension, palpitation, vasodilation, cerebral thrombosis, pulmonary edema, tachycardia.
From the urinary system rarely – dysuria, frequent urination, urinary retention, anuria, polyuria, kidney stone formation, renal failure, nephritis, hematuria, albuminuria, candiduria.
From the musculoskeletal system rarely – arthralgia, myalgia, tendinitis, muscle weakness, exacerbation of myasthenia.
From metabolism rarely – thirst, weight loss, hyper- or hypoglycemia (especially in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents), acidosis, increase in serum TG, cholesterol, potassium.
From the respiratory system rarely – cough, nasal discharge, respiratory arrest, dyspnea, bronchospasm, stridor.
From the senses rarely – hearing impairment, tinnitus, diplopia, nystagmus, impaired visual acuity, disorders of taste, smell, photophobia.
Dermatological reactions rarely – photosensitivity, hyperpigmentation, vesiculobullous eruptions.
From the hematopoietic system rarely – anemia, bleeding, pancytopenia, agranulocytosis, leukopenia, reversible bone marrow depression, thrombocytopenia, thrombocytopenic purpura, petechiae, ecchymoses, increased prothrombin time.
Other chest pain, pharyngitis, increased body temperature, body aches; rarely – asthenia, chills, general malaise, nosebleed, increased sweating.
Contraindications
Hypersensitivity to ofloxacin or other quinolone derivatives; tendon damage during previous treatment with fluoroquinolones, epilepsy (including history), lowered seizure threshold, chronic renal failure (CrCl<50 ml/min); pregnancy, breastfeeding period; children and adolescents under 18 years of age.
Use in Pregnancy and Lactation
Use is contraindicated during pregnancy and breastfeeding.
Use in Hepatic Impairment
It should be used with caution in patients with impaired liver function. Do not exceed the daily dose of 400 mg.
Use in Renal Impairment
It should be used with caution in patients with impaired renal function.
Pediatric Use
Use is contraindicated in children and adolescents under 18 years of age.
Geriatric Use
In elderly patients, it should be used with caution, taking into account the state of renal function.
Special Precautions
During treatment, blood glucose levels should be monitored. During long-term therapy, renal function, liver function, and peripheral blood picture should be periodically monitored.
When using ofloxacin, adequate hydration of the body should be ensured, and the patient should not be exposed to UV radiation.
In experimental studies, no mutagenic potential was identified. Long-term studies to determine the carcinogenicity of ofloxacin have not been conducted.
In studies on young animals of several species, Ofloxacin caused arthropathy and osteochondrosis.
The safety and efficacy of the drug in children and adolescents under 18 years of age have not been established.
Effect on ability to drive vehicles and mechanisms
During the use of the drug, patients should exercise caution when driving vehicles and mechanisms, as well as when engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Drug Interactions
With simultaneous use with antacids containing calcium, magnesium or aluminum, with sucralfate, with preparations containing divalent and trivalent cations such as iron, or with multivitamins containing zinc, impaired absorption of quinolones is possible, leading to a decrease in their concentration in the body. These drugs should not be used within 2 hours before or within 2 hours after taking ofloxacin.
With simultaneous use of ofloxacin and NSAIDs, the risk of developing a stimulating effect on the central nervous system and convulsions increases.
With simultaneous use with theophylline, an increase in its plasma concentration (including at steady state) and an increase in T1/2 are possible. This increases the risk of adverse reactions associated with the action of theophylline.
With simultaneous use of ofloxacin with beta-lactam antibiotics, aminoglycosides and metronidazole, an additive interaction was noted.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer